Corcept Q4 Revenue Misses by 18.5% as Margin Slumps to 2.2%
Corcept Therapeutics reported Q4 CY2025 revenue of $202.1 million, up 11.1% year-over-year but 18.5% below analysts' $247.9 million estimate. GAAP EPS of $0.20 missed consensus by 26.3% and operating margin plunged to 2.2% from 13.9% a year earlier.
1. Q4 Sales Shortfall
Corcept delivered Q4 CY2025 revenue of $202.1 million, marking an 11.1% year-over-year increase but falling 18.5% short of the $247.9 million analyst estimate.
2. Profit and Margin Pressure
GAAP EPS of $0.20 missed the $0.27 target by 26.3% while operating margin collapsed to 2.2%, down from 13.9% in the same quarter last year, reflecting rising expenses outpacing sales.
3. Market Reaction and Outlook
Shares dropped 3.8% to $35.07 post-report; sell-side analysts project 9.5% revenue growth and expect full-year EPS to decline 30.3% to $0.83 over the next 12 months.